by Symmetron | Jan 19, 2019
atrial fibrillation Economic evaluation of insertable cardiac monitors in detecting previously undiagnosed atrial fibrillation and subsequently moderating stoke risk in a high-risk population in the United Kingdom Presented at ESC Congress. August 25-29, 2018....
by Symmetron | Jan 18, 2019
atrial fibrillation Economic evaluation of insertable cardiac monitors to detect atrial fibrillation and subsequently moderate stroke risk in a high-risk population in the UK Presented at ISPOR Europe. November 10-14, 2018. Barcelona, Spain. Authors C. Rinciog, L....
by Symmetron | Jan 18, 2019
atrial fibrillation Cost-effectiveness of an insertable cardiac monitor to detect atrial fibrillation in patients with cryptogenic stroke. International Journal of Stroke. 2016;11(3):302-12 Authors Diamantopoulos A, Sawyer LM, Lip GY, Witte KK, Reynolds MR, Fauchier...
by Symmetron | Jan 18, 2019
Idiopathic Pulmonary Fibrosis Pharmacoeconomic Assessment of Nintedanib For The Treatment of Idiopathic Pulmonary Fibrosis In The Greek Healthcare System Presented at ISPOR Europe. October 29 to November 2, 2016. Vienna, Austria. Authors Triaki G, Souliotis K, Bouros...
by Symmetron | Jan 18, 2019
Idiopathic Pulmonary Fibrosis Cost-Effectiveness of Nintedanib in Idiopathic Pulmonary Fibrosis in the U.S. Presented at AMCP NEXUS. October 22-25, 2018. Orlando, USA Authors Rinciog C, Bermingham S, Cornic L, Diamantopoulos A, Fan Y Process \ A \ B \...
Recent Comments